KRAS Codon 12 Mutations and Detection

by | Aug 22, 2019 | Blog

The KRAS gene is one of the major oncogenes whose mutations can lead to different types of cancer. KRAS, along with other RAS genes, NRAS and HRAS, is a RAS gene family member in the RAS/MAPK signal pathway that passes the signal from receptor tyrosine kinases (RTKs) to regulate cell proliferation, differentiation and programmed cell death (apoptosis). RAS mutations are found in 30% of all human cancers.

KRAS Gene Mutations

The K-Ras protein performs its regulatory role in signal transduction through its GTPase activity. Important KRAS mutations abolishes the normal KRAS regulatory role in response to signal transduction and lead to constitutively active KRAS regardless of cell signals. These KRAS mutations with clinical significance include mutations at different codons, including 12 (80%), 13 (17%), 61 and 146 (1 to 4%). These mutations are found in different types of cancers including lung cancer (non-small cell lung cancer, NSCLC accounts for 85% of lung cancer), colorectal cancer (CRC, 96% of CRCs are adenocarcinoma), pancreatic cancer (94% of pancreatic cancers are exocrine tumors) and others. Among these codons, codon 12 is the most important codon that can change from glycine to several different amino acids.

Here is the KRAS G12 mutation rates in NSCLC or CRC according to my cancer genome.

  • G12A: 2.39% in NSCLC and 2.12% in CRC
  • G12C: 11.77% in NSCLC and 3.22% in CRC
  • G12D: 4.09% in NSCLC and 12.83% in CRC
  • G12R: 0.38% in NSCLC and 0.43% in CRC
  • G12S: 0.5% in NSCLC and 1.84% in CRC
  • G12V: 5.32% in NSCLC and 8.92% in CRC

Drug Development Targeting KRAS Mutations

Targeted therapy based on oncogene primary and secondary mutations has motivated pharmaceutical companies to develop targeted drugs such as different generations of tyrosine kinase inhibitors for different EGFR mutations. However, KRAS was thought as undruggable until recently when Amgen has developed the first KRAS drug AMG 510targeting KRAS G12C. Mirati Therapeutics is also developing a KRAS G12C drug.

Detection of KRAS Mutations

Although multiple vendors have developed commercial kits for KRAS mutation detection, mainly based on qPCR techniques. The analytical sensitivity varies dramatically from 1 to 10% VAF (Variant Allele Frequency) between the different mutations or detection kits. It is critical to detect these mutations with highly sensitive assays for early cancer detection.

We have developed the KRAS assay by adding the novel wildtype sequence of XNA(xenonucleic acids) into the qPCR assay to increase the assay sensitivity (clinical samples at 0.1 to 0.5% VAF) for detection of 1 to 3 copies of mutant allele. Our assay covers six KRAS codons 12, 13, 59, 61, 117 and 146 and can be performed by commonly used qPCR instruments (validated for Thermo Fisher QuantStudio 5, Bio-Rad CFX384 and Roche LC-480II). The assay uses either 10 ng of FFPE DNA or plasma cfDNA samples for detection of each codon mutation. We can either accommodate your needs for one codon mutation or all the six codon mutations in the whole KRAS kit.

Lead Source

HPV-driven Cancers and Somatic Mutations in These Cancers

Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.

cfDNA Quantitation for Research and Clinical Applications

Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.

Confirmation of NGS for False-negative Variants Using XNA Technology

Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.

XNA Molecular Clamps Help Identify False-positive T790M Mutation

Eighty five percent of the lung cancer patients are non-small cell lung cancer (NSCLC) patients. Among this population, patients with exon 19 deletion and L858R mutations respond well to the first (such as erlotinib and gefitinib) and second generation (such as afatinib and dacomitinib) of tyrosine kinase inhibitors (TKIs). However, all the respondents develop resistance after 9 to 14-month period and more than 50% of the resistance cases are due to the single point mutation at exon 20, T790M.

Colorectal Cancer: Early Screening Could Save Your Life

linkedinfacebooktwitterColorectal cancer (CRC), including colon and rectum cancer, is the third most common cancer in the world and the third in the US as well. American Cancer Society (ACS) estimates that there are 97,220 and 43,030 new cases in 2018 for colon and...

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

X